John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening Accessibility StatementSkip Navigation ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom family members, John Stamos and Jodie Sweetin, for "The (Second) Talk" campaign – because when it comes to colon cancer screening, ...

一众跨国医械集团领导人正齐聚北京！ 3月22日至23日，2026年中国发展高层论坛在北京隆重召开，吸引了全球工商界、国际组织及世界500强企业的100多位外方代表出席。其中，12家跨国医 疗企业高管受邀参会，涵盖美敦力公司全球董事长兼首席执行官杰夫·马萨（Geoff Martha）、西门子医疗全球首席执行官孟天齐（Bernd Montag）、雅培 公司董事长兼首席执行官罗赋德（Robert Ford）、直观医疗首席执行官罗岱威（Dave J.Rosa）、欧加隆代理首席执行官约瑟夫·莫里斯（Joseph Morrissey）、罗氏集团董事会主席施万（Severin Schwan）、赛默飞世尔科技董事长兼首席执行官葛士柏（Marc Casper）等知名医疗器械领域龙头企业。 器械之家整理了会议期间，医械行业领导人的会议行程和重要讲话内容，其中密集释放了加码在华投资、深化本土合作的明确信号，彰显了中国市场在全 球医械产业格局中的核心地位。 01 高层会见搭桥梁 论坛开幕前夕，跨国医械企业高管已开启密集对接交流，为深化在华合作奠定基础。3月21日下午，商务部部长王文涛在北京集体会见美国药品研究与制 造企业协会总裁兼首 ...

Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now. Following encouraging results from Abbott Laboratories (NYSE:ABT)’s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company’s shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology ...

2026.03. 24 本文字数：2990，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 "十五五"规划纲要明确提出实施健康优先发展战略，并将生物制药列为新兴支柱产业，为跨国医药企 业参与"健康中国"建设提供了新机遇。 近日，"中国发展高层论坛2026年年会"（下称"年会"）召开。年会期间，国家卫健委和中央财经委等 有关部门均释放了深化医药卫生体制改革、促进医疗等重点领域科技创新、优化营商环境和加大对外 开放的积极信号。 多名与会跨国医药企业高管均积极回应，将扩大在华业务，加大在细胞疗法等前沿领域的本地化生产 能力，继续投资本地创新并加强创新合作。 在深度参与中国医药创新的过程中，这些跨国医药企业对中国医药创新生态也有更多期待：其一，优 化完善与创新相匹配的知识产权保护体系、价值认定和支付机制，为企业提供制度性激励；其二，以 临床需求为导向，推动市场和监管的关注点从产品创新转向系统性集成创新，加大中国在疾病治理和 创新方案上的输出能力，完善涵盖患者、医疗机构、国内外制药企业和科研院所、社会资本以及监管 部门等多方的医药创新生态。 跨国药企深化在华布局 据国家卫健委消息，22日，上述年会"谋划'十五五'国民健 ...

Core Viewpoint - Abbott has completed the acquisition of Exact Sciences, positioning itself as a leader in the rapidly growing cancer screening and diagnostics market, thereby expanding its ability to serve millions more people [1][2][8]. Group 1: Acquisition Details - The acquisition of Exact Sciences has made it a wholly owned subsidiary of Abbott, with the last trading day for Exact Sciences shares on Nasdaq being March 20, 2026 [2]. - This strategic move is expected to enhance Abbott's operational and commercial capabilities in cancer care, leveraging Exact Sciences' expertise [2][3]. Group 2: Strategic Fit - The transaction allows Abbott to advance its diagnostics offerings, focusing on preventative, predictive, and personalized healthcare solutions in response to the rising global cancer incidence [3]. - Abbott aims to establish leadership in the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical to its existing high-single-digit growth expectations [3]. Group 3: Product Offerings and Pipeline - Abbott now possesses a comprehensive suite of cancer detection products, including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard®, which are designed for early detection and personalized treatment [4][5]. - The company is also enhancing its pipeline with next-generation cancer screening technologies aimed at earlier detection and better disease management [5].

Core Viewpoint - Abbott's acquisition of Exact Sciences for approximately $21 billion (about 145 billion RMB) marks a strategic entry into the high-growth tumor early screening and precision oncology market, addressing a significant gap in Abbott's capabilities in tumor early screening and molecular diagnostics [2][4][5][6]. Group 1: Acquisition Details - The acquisition has received all regulatory approvals and is in the closing phase, indicating a smooth transition into Abbott's portfolio [2]. - Exact Sciences is a key player in the U.S. tumor screening and molecular diagnostics field, with core products including non-invasive colorectal cancer screening and multi-cancer early detection [2][5]. Group 2: Market Context - The tumor diagnosis field is shifting from "post-diagnosis testing" to "screening asymptomatic populations," with Exact Sciences representing a new technological pathway [8][9]. - Abbott's entry signifies a transition from innovation-led companies to a phase dominated by large corporations and scale competition in the tumor early screening market [10][11]. Group 3: Strategic Implications - Abbott aims to tap into a market valued at approximately $60 billion, positioning it as a new growth engine for the company [6]. - The acquisition reflects a willingness to incur significant debt (around $20 billion) to secure a foothold in this emerging market [7]. Group 4: Insights for the Chinese Market - The tumor early screening market in China is rapidly evolving, with key players like NuoHui Health and Burning Stone Medical emerging [16]. - The transaction signals that future competition will hinge on comprehensive capabilities, including channels, payment systems, branding, and scale, rather than solely on technology [17]. - The trend of multinational giants acquiring new technologies rather than relying solely on in-house development is reinforced by this acquisition, highlighting the importance of channel and payment capabilities in accessing healthy populations [20][21]. Group 5: Conclusion - This acquisition is not merely a transaction but a strategic shift towards future healthcare demands, emphasizing the need for early disease detection rather than treatment [22][23]. - The ability to control early screening access will be crucial in determining the future landscape of the healthcare system, with Abbott's investment underscoring the value of this entry point [24].

Market Overview - The S&P 500 has lost positive momentum since the start of the year after a strong three-year performance, influenced by concerns over the AI market's long-term revenue potential, economic uncertainty, interest rate cuts, and geopolitical tensions such as the war in Iran [1] Defensive Stocks Recommendation - It is suggested to add defensive stocks to portfolios, particularly in the healthcare sector, as these companies tend to perform well even in challenging economic conditions [2] Company Analysis: Abbott Laboratories - Abbott Laboratories is favored due to its diversified healthcare business, which includes medical devices, diagnostics, nutrition, and established pharmaceuticals, allowing it to mitigate risks from any single segment [3] - The company's essential products make its revenue less susceptible to economic fluctuations [4] - Abbott has a market capitalization of $183 billion, a gross margin of 52.72%, and a dividend yield of 2.28%, having increased its dividend payments for over 50 consecutive years, indicating strong financial health and commitment to shareholder returns [5][6] Company Analysis: Intuitive Surgical - Intuitive Surgical is recognized as the global leader in robotic surgery, particularly with its Da Vinci surgical robots, which have contributed to consistent earnings growth [7] - The company benefits from a strong competitive advantage, as most surgeons are trained on Da Vinci systems, leading to a preference for these devices in surgical settings [9] - Intuitive Surgical has a market capitalization of $170 billion, a gross margin of 65.98%, and generates recurring revenue through the sale of accessories and instruments needed for surgeries, making it a resilient stock during market downturns [10]

Core Thesis - Abbott Laboratories (ABT) is viewed positively due to its diversified healthcare model, strong market position in medical devices, and consistent dividend growth, despite facing near-term challenges [1][6]. Company Overview - Abbott Laboratories is a global healthcare company involved in medical devices, diagnostics, nutrition, and established pharmaceuticals, with nearly 70% of its revenue coming from medical devices and diagnostics [3]. - Key products include the FreeStyle Libre glucose monitor and heart repair devices, which contribute to a competitive advantage through patents and high switching costs [3]. Financial Performance - As of March 6th, ABT's share price was $109.56, with trailing and forward P/E ratios of 29.45 and 19.30, respectively [1]. - The company has a strong balance sheet, featuring a debt-to-equity ratio of 30% and an interest coverage ratio of 75, alongside robust free cash flow generation [5]. - Abbott has maintained a dividend growth streak of 54 consecutive years, with a 5-year compound annual growth rate (CAGR) of 9.4% [5]. Market Challenges - Abbott faces several near-term challenges, including legal liabilities related to specialty infant formula, weakened demand post-price increases, declining COVID-testing revenues, and pricing pressures in China, contributing to a stock decline of approximately 15% this year [4]. - The dividend yield has approached 2.4% due to these pressures [4]. Long-term Outlook - Despite current headwinds, Abbott is well-positioned for long-term growth due to favorable trends in chronic disease management, an aging population, and emerging middle-class markets [5]. - The company's management, led by CEO Robert B. Ford, has a proven track record in navigating complex markets and executing acquisitions, such as the $21 billion Exact Sciences deal aimed at cancer diagnostics [4][5]. - For long-term investors, Abbott represents a compelling opportunity with a mix of defensive characteristics and innovation-driven growth potential [6].

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

Two fields in particular draw attention when we look at Abbott. The company’s FreeStyle Libre product is a leader in the continuous glucose monitoring (CGM) market, a vital technology in controlling and managing diabetes. Abbott’s product boasts that it is the leading CGM brand in the US. Abbott’s cardiovascular products include devices to manage such conditions as heart failure, irregular heartbeat, and mitral regurgitation.The first company we’ll look at, Abbott Laboratories, was founded in 1888 – and has ...